Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

IMPORTANCE: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. OBJECTIVE: To evaluate the efficacy and safety of fingolimod, 0.5 mg, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce A. C., Goldman, Myla D., Corboy, John R., Singer, Barry A., Fox, Edward J., Arnold, Douglas L., Ford, Corey, Weinstock-Guttman, Bianca, Bar-Or, Amit, Mientus, Susanne, Sienkiewicz, Daniel, Zhang, Ying, Karan, Rajesh, Tenenbaum, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445630/
https://www.ncbi.nlm.nih.gov/pubmed/32852530
http://dx.doi.org/10.1001/jamaneurol.2020.2950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445630/
https://www.ncbi.nlm.nih.gov/pubmed/32852530
http://dx.doi.org/10.1001/jamaneurol.2020.2950

Ejemplares similares